ViewsML Raises Capital to Build ‘Computational Layer for Next-Gen Diagnostics’

A Vancouver-based company building a computational layer for biomarker discovery has secured seed capital.

Transforming tissue analysis from a lab process into software, ViewsML garnered $4.9M from Wittington Ventures alongside Continuum Health Ventures, Mayo Clinic, RiSC Capital, Debiopharm, WUTIF, Defined, and e-Fund.

The B.C. startup is “dedicated to leveraging the power of AI to accelerate the delivery of precision medicines and make them accessible to patients worldwide.”

Demand for scalable, high-resolution biomarker data grows across drug development and diagnostics. ViewsML’s technology represents the world’s first virtual biomarker library using artificial intelligence to generate per-cell biomarker spatial insights from pathology images without the need for laboratory staining, according to a statement from the firm.

“Biomarkers are foundational to how we understand and treat disease, yet the way we measure them remains constrained by legacy approaches,” explains Zeeshan Ali, Partner, Wittington Ventures.

ViewsML is “redefining how biomarkers are measured and analyzed–unlocking a step-change in speed, scale, and accessibility across research and clinical settings.”

Virtual staining “has the potential to accelerate workflows, lower costs, and unlock new applications across translational research, diagnostics, clinical trials and emerging areas such as neurodegenerative disease,” Ali said, “driving faster insights and improved patient outcomes.”

The capital will be used to accelerate commercialization of ViewsML’s platform and bolster strategic collaborations with healthcare institutions, diagnostic companies, and biopharma organizations, according to chief executive officer Kenneth To.

“We’re building the computational layer for next-generation diagnostics,” says To.

“This capital will enable us to fast-track our efforts to revolutionize immunohistochemistry,” the CEO remarked. “By building the world’s first virtual biomarker library, we’re going to empower scientists and clinicians to analyze biomarker staining in minutes rather than the traditional days or weeks.”

To’s upstart is attending the American Association for Cancer Research Annual Meeting at the San Diego Convention Center.

ViewsML was founded in 2022.